The best characterized biological fluid markers for AD are decreased levels of amyloid β-protein (Aβ) 42 and increased levels of phosphorylated tau and total ...

Jan 1, 2016 · Further, the Aβ42/Aβ40 and Aβ42/Aβ38 ratios showed increased accuracy compared to Aβ42 when distinguishing AD from dementia with Lewy bodies or ...

Sep 13, 2023 · Diagnosis of dementia with Lewy bodies (DLB) is challenging and specific biofluid biomarkers are highly needed.

Jul 9, 2013 · ... CSF amyloid beta38 as a novel diagnostic marker for dementia with Lewy bodies. ... B: Clinical diagnostic criteria for dementia associated ...

CSF AD biomarker profile was seen in 47% of patients with dementia with Lewy bodies (DLB), 38% in corticobasal degeneration (CBD), and almost 30% in ...

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. ... amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.

Apr 21, 2023 · Cerebrospinal fluid (CSF) reflects the biological state of the brain and can provide valuable insights into the progression of dementia.

As the differential diagnosis of dementias based on established clinical criteria is often difficult, biomarkers for ... dementia; cerebrospinal fluid; amyloid-b ...

Aug 18, 2019 · The outcomes, although controversial, showed that α-synuclein in the CSF is a reliable biomarker for the differential diagnosis between DLB and ...

DLB and PDD were combined in a Lewy body dementia group (LBD). No differences were observed in sAPPα and sAPPβ levels between the groups. Significant ...